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PERANAN RANIBIZUMAB SEBAGAI AGEN ADJUNKTIF KEPADA 
RAWATAN-MITOMYCIN-C DALAM PENGIMPLANAN TIUB 




Kadar rembesan vascular endothelial growth factor (VEGF) yang tinggi 
kebiasaanya berlaku selepas pembedahan glaukoma. Namun, hal ini tidak diingini 
oleh kerana ia menyebabkan berlakunya penyembuhan luka/parut yang berlebihan 
seterusnya menggagalkan tujuan sebenar pembedahan. Oleh yang demikian, kajian 
ini mencadangkan potensi fungsi ranibizumab, iaitu anti – vascular endothelial 
growth factor (anti – VEGF), sebagai agen adjunktif dalam mencegah/ menghalang 
pembentukan fibrosis yang berlebihan. Tujuan kajian ini dijalankan adalah untuk 
menentukan kesan rawatan ranibizumab bersama mitomycin – C ke atas proliferasi, 
toksisiti dan migrasi sel fibroblas konjunktiva mata manusia (HConFs). Dalam kajian 
proliferasi dan toksisiti, HConFs dikulturkan dalam medium fibroblas dan dirawat 
dengan mitomycin-C (MMC) 0.40 mg/ml. Kultur ini kemudian dirawat dengan 
ranibizumab yang berbeza kepekatan/dos (0 mg/ml, 0.30 mg/ml, 0.45 mg/ml dan 
0.60mg/ml). Pembiakan kultur HConFs tersebut dinilai selepas 24, 48 dan 72 jam 
menggunakan ujian alamarBlue. Untuk toksisiti pula, kadar kematian sel secara 
apoptosis dibaca menggunakan mesin flow cytometri yang ditandakan dengan 
Annexin-V FITC dan propidium iodide, 72 jam selepas rawatan. Sementara itu, 
untuk kajian morfologi dan migrasi HConFs, model implantasi tiub glaukoma secara 
in vitro telah dibuat. Menggunakan model tersebut, HConFs telah dirawat mengikut 
4 kumpulan iaitu; kawalan, MMC 0.40 mg/ml, ranibizumab 0.45 mg/ml and MMC 
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0.40 mg/ml+ranibizumab 0.45 mg/ml. Kadar migrasi HConFs ke dalam tiub 
diperhatikan pada hari ke – 7, 14 dan 21 menggunakan ujian alamarBlue dan 
scanning electron microscope (SEM). Aplikasi ranibizumab bersama MMC telah 
menghalang proliferasi HConFs secara signifikan pada 48 dan 72 jam rawatan. 
Kadar proliferasi HConF bergantung kepada dos, iaitu proliferasi telah dikurangkan 
secara signifikan oleh ranibizumab pada dos 0.45 mg/ml, (p<0.05). Menariknya, 
jumlah HConFs didapati tinggi pada dos ranibizumab 0.60 mg/ml berbanding 
kumpulan rawatan lain. Selain itu, rawatan ranibizumab juga didapati merangsang 
apoptosis dan mengurangkan nekrosis HConFs. Kadar apoptosis yang tertinggi serta 
kadar nekrosis yang terendah diperhatikan dalam kumpulan rawatan ranibizumab 
0.45 mg/ml. Sementara itu, kajian migrasi fibroblas ke dalam tiub selepas 7 hari 
menunjukkan kadar migrasi yang rendah dalam kumpulan MMC dan 
MMC+ranibizumab berbanding kawalan (p<0.05). Rawatan MMC menunjukkan 
peratusan migrasi yang sedikit rendah berbanding MMC+ranibizumab, 
(p=0.792). Berbeza pula dengan kumpulan yang dirawat dengan ranibizumab, 
peratusan migrasi fibroblas yang lebih tinggi berbanding kawalan, (p=0.985). 
Manakala, pada hari ke – 14 dan 21, peratusan migrasi fibroblas didapati hampir 
sama dalam semua kumpulan (p<0.05) dan (p=0.248). Kesimpulannya, aplikasi 
ranibizumab telah mengurangkan lagi proliferasi HConFs yang dirawat oleh MMC 
dengan menambahkan lagi apoptosis serta mengurangkan nekrosis. Namun, 
ranibizumab sahaja tidak berupaya untuk mengurangkan kadar migrasi HConFs ke 
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Elevated expression of vascular endothelial growth factor (VEGF) usually 
occurs after the glaucoma surgery. The elevated expression of VEGF is unnecessary 
as it contributes to excessive scarring which will fail the surgery. Therefore, this 
study investigated the potential role of ranibizumab, an anti – vascular endothelial 
growth factor (anti – VEGF), as anti – adjunctive agent in preventing the excessive 
fibrosis. The aim of this study is to determine the effect of adjunctive use of 
ranibizumab with mitomycin – C on proliferation, cytotoxicity and migration of 
human conjunctival fibroblasts (HConFs) cell line. In proliferation and cytotoxicity 
study, HConFs were cultured in fibroblast medium and treated with 0.40 mg/ml 
mitomycin – C (MMC). The cultures were then administered with ranibizumab at 
different concentration (0 mg/ml, 0.30 mg/ml, 0.45 mg/ml and 0.60mg/ml). Viability 
and proliferation of HConFs were assessed at 24, 48 and 72 hours by alamarBlue 
assay. For cytotoxicity, the apoptosis rate of treated HConFs was evaluated via flow 
cytometry using Annexin-V FITC and propidium iodide staining after 72 hours 
treatment. Meanwhile, for morphology and migration study, in vitro model of 
glaucoma tube implantation was used. HConFs were treated according to 4 groups; 
control, MMC 0.40 mg/ml, ranibizumab 0.45 mg/ml and MMC 0.40 mg/ml 
+ranibizumab 0.45 mg/ml. Migration of HConFs onto the tube was observed at day 
7,14 and 21 through alamarBlue assay and scanning electron microscope (SEM). 
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Application of ranibizumab following MMC caused a dose – dependent inhibition of 
HConF’s viability and proliferation which significant after 48 and 72 hours. It was 
shown that HConF’s proliferation was significantly reduced by ranibizumab at 
concentration 0.45 mg/ml, (p<0.05). In fact, surprising higher number of HConF was 
noted in 0.60 mg/ml ranibizumab group in contrast to other treatment groups. 
Concurrently, treatment of ranibizumab also found to induce apoptosis and reduced 
necrosis among HConFs. The highest level of apoptotic HConFs and the least 
necrotic HConFs were observed at concentration 0.45 mg/ml. While in tube 
migration study, 7 days treatment resulted in lower percentages of HConFs migrated 
on to the tube observed in MMC and MMC+ranibizumab treated group compared to 
control, (p<0.05). Treatment of MMC showed lower percentage of migrated 
fibroblasts than MMC+ranibizumab group, (p=0.792). In contrast, higher percentage 
of migrated fibroblasts was observed in ranibizumab group with respect to control, 
(p=0.985). Whereas, at day 14 and 21, percentage of migrated fibroblasts is almost 
the same in all groups, (p<0.05) and (p=0.248), respectively. In conclusion, 
application of ranibizumab could further inhibit the proliferation of MMC treated 
HConFs by increasing the apoptosis and reducing the necrosis. It was also discovered 
that ranibizumab alone was not effective in suppressing the migration of HConFs 
onto the glaucoma tube. Instead, the adjunctive treatment of MMC and ranibizumab 






1.1 Overview on Glaucoma 
Glaucoma is defined as optic neuropathy characterized with specific visual 
field defect and specific optic disc cup ratio. It is a pathologic condition in which the 
optic nerves called ganglion cell axons undergo a progressive loss causing visual 
field damage (Figure 1.1). This condition usually caused by abnormal high pressure 
inside the eye known as intraocular pressure (IOP). If left untreated, glaucoma may 
lead to irreversible blindness. Several treatments are available to prevent the further 
loss of vision caused by glaucoma. One of them is glaucoma filtration surgery for 
implantation of glaucoma drainage devices (Rhee, 2012). 
 
Figure 1.1 Pathologic condition of glaucoma due to abnormal high intraocular 




1.2 Glaucoma Filtration Surgery 
Glaucoma filtration surgery including trabeculectomy, non – penetrating 
surgery technique and aqueous shunts functions to drain out aqueous humor to the 
sub – tenon space. All these types of filtration surgery depend on external resistance 
created by wound healing. The success of these surgical procedure is hindered by the 
variability of wound healing response. Inadequate healing response will results in 
hypotony while vigorous healing response causes high IOP to re – occur (Mathew 
and Barton, 2011). 
Filtration surgery remains as the most effective therapy in lowering 
intraocular pressure (IOP) in glaucoma patients. However, excessive post – operative 
scarring of the conjunctiva and tenon at the surgical site leads to the failure of the 
surgery. Excess scar formation because of increased wound healing response after 
the surgery, obstructs the aqueous humor outflow causing poor IOP control, hence 
reduced the surgical outcome (Bochmann et al., 2011; How et al., 2010; Li et al., 
2009).  
 
1.3 Glaucoma Drainage Devices  
Glaucoma drainage devices (GDDs) are devices that was designed to lower 
intraocular pressure (IOP) (Figure 1.2). They are also known as aqueous shunts, 
aqueous shunting devices or tube shunts. GDD is traditionally used in cases of failed 
filtration surgery, recalcitrant and complex glaucomas such as inflammatory, 
neovascular and traumatic glaucoma. Nowadays, increasing number of publications 
on GDDs allow the use of GDDs as primary glaucoma surgery (Rhee, 2012). 
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Made of medical grade silicone, there are two types of GDDs which are 
restrictive (Ahmed and Krupin) and nonrestrictive (Molteno and Baerveldt) models 
(Figure 1.3). Non-restrictive or non-valved devices permit the free flow of aqueous 
from inside the eye to episcleral platewhile the restrictive or valved devices  have a 
flow – controlling element within the posterior part of the tube to limit the aqueous 
flow (Rhee, 2012). 
 
Figure 1.2 Parts of glaucoma drainage device (GDD). 
 
 
Figure 1.3 Different types of GDD. From left to right showing Krupin, 
Baerveldt, Ahmed valve, two – plate Molteno and Molteno implants.  Picture 







Figure 1.4 Glaucoma tube shunt implantation in patient’s eye. End of the tube is 
inserted into the anterior chamber while the plate is placed on the surface of eyeball, 
underneath the conjunctiva (MohawkValleyRetina, 2017). 
 
1.4 Ocular Wound Healing 
Fibroblasts in the tenon’s capsule are the key player in ocular wound healing 
(Li et al., 2009). They are the cells that function for generating a contractile force, 
which is essential in the post – operative scarring process. The scarring can develop 
through the proliferation, migration and contraction of  the fibroblasts. Fibroblasts 
are stimulated by growth factors to differentiate into myofibroblasts. Myofibroblasts 
are responsible for fibrosis through the  increased of extracellular matrix (ECM) 
synthesis, for granulation tissue formation, and wound contraction (Honjo et al., 
2007; Horsley and Kahook, 2010). 
After the glaucoma surgery, conjunctival and episcleral fibrosis (which is 
fibroblast mediated) occurs due to progressive fibroblast migration, proliferation, 
collagen deposition and angiogenesis at the site of the filtration bleb. From histologic 
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studies, the maximum proliferation of subconjunctival fibroblasts occurs in the third 
to fifth postoperative day (Mathew and Barton, 2011; Memarzadeh et al., 2009). 
There are four sequential processes in wound healing which are angiogenesis, 
migration and proliferation of fibroblasts, deposition of ECM (scar formation) and 
maturation and reorganization of the fibrous tissue (remodelling) (Kumar, 2007). 









1.4.1 Vascular Endothelial Growth Factor (VEGF) 
Vascular endothelial growth factor (VEGF) is the protein growth factor that 
plays an important role in building up the circulatory system under the physiological 
conditions (Barrett et al., 2010; Takahashi, 2011). It was first described as a 
molecule that increases the permeability of blood vessels and stimulates the 
production of new blood vessels (Bochmann et al., 2011). VEGF induced the 
formation of vascular (vasculogenesis) during embryonic development and growth of 
blood – vessels (angiogenesis) in adults (Ferrara, 2004; Olsson et al., 2006).  
Cell-mediators and growth factors such as VEGF are essential in wound 
healing mechanism. Once the balance of these growth factors is disturbed, altered 
wound-healing processes with extensive scar formation may occur. In cutaneous 
wounds, high level of VEGF induces scar formation through increasing vascularity 
and collagen deposition, whereas neutralization of the VEGF reduces angiogenesis 
and cutaneous fibrosis (Li et al., 2009). 
 
1.4.2 Angiogenesis 
Angiogenesis is the formation of new blood vessels from pre-existing 
vasculature (Olsson et al., 2006). It is a critical process in healing that provides the 
blood supply for the tissues. Abnormally, it is important for tumor growth in which if 
tumors do not develop a blood supply, they do not grow. VEGF is a key compound 
in physiological angiogenesis and serves as a major stimulator in pathological 
angiogenesis (Barrett et al., 2010; Stewart, 2012; Takahashi, 2011). In condition of 
neovascularisation and in malignant tumor, VEGF is over expressed enable them to 
growth and metastasize (Bochmann et al., 2011).  
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Angiogenesis allows the early migration of inflammatory cells and fibroblasts 
into wound and release the key mitogenic cytokines such as fibroblast growth factor 
(FGF). Blocking the angiogenic cascade will reduce the migration and proliferation 
of the fibroblast and consequently slow down the healing response (Memarzadeh et 
al., 2009). This inhibition can be occur through the use of selective inhibitor of 
growth factor such as anti – VEGF. Anti – VEGF monoclonal antibodies can be used 
as an approach in preventing or treating extensive wound healing with over 
expression of VEGF (Bochmann et al., 2011). 
 
1.4.3 Fibroblast Migration and Proliferation 
Few days after the wound occurs, fibroblast begin to migrate from adjacent 
uninjured tissue to the wound site through fibronectin fibrils (Hsieh and Chen, 1983). 
It then proliferates and accumulates in the wound to reconstitute a variety of 
connective tissue components. This proliferation phase occured simultaneously with 
angiogenesis.  
Fibroblasts migration and proliferation are vital in wound granulation. 
Initially, cellular blood constituents such as platelets and monocytes release various 
peptide growth factors [for instance platelet – derived growth factor (PDGF) and 
transforming growth factor-β (TGF-β)] to stimulate the migration of fibroblasts. 
More mediators are produced which draw the fibroblasts, neutrophils, mast cells, 
endothelial cells and basal cells to migrate to wound. Finally, the tissue granulation 





1.5 Cell Death 
Cell death is necessary for development, growth and survival of any living 
thing. For instance, cell death is required during embryogenesis in tissue sculpting, 
development of the immune system and destruction of damaged cells (Tait et al., 
2014). There are two broad, mutually exclusive classification of cell death; necrosis 
and apoptosis (Galluzzi et al., 2015). In senescent human fibroblasts in vitro, it was 
suggested that both apoptosis and necrosis are involved in the cell death (Ohshima, 
2006). 
1.5.1 Necrosis 
Severe insults/injury due to  physical (e.g.,heat or radiation), chemical (e.g.,extreme 
changes in pH or potent detergent) and mechanical (e.g., shearing) stimuli caused the 
cell to die through necrosis (Galluzzi et al., 2015). These acute injuries typically 
results in cells swelling and burst. Their contents are spilled all over the adjacent 
uninjured cells causing potentially destructing inflammatory response (Alberts et al., 
2002). Necrosis is commonly associated with pathological process (Adigun R, 2018). 
 
1.5.2 Apoptosis  
Meanwhile, another distinct cell death mode is a programmed cell death called 
apoptosis. The term of apoptosis was introduced by Kerr in 1971 (derived from a 
Greek word meaning “falling off” like leaves from a tree (Alberts et al., 2002; Kerr, 
1971). Apoptosis normally occurs in multicellular organism, as homeostasis 
mechanism to sustain the cell population in tissue by control of cell division and 
death. When the cells are no longer needed, they commit suicide by apoptosis 
(Alberts et al., 2002; Elmore, 2007). Apoptosis also occurs as defense mechanism to 
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the various of noxious stimuli. Both physiological and pathological may trigger the 
apoptosis (Adigun R, 2018; Elmore, 2007; Norbury and Hickson, 2001).  
In apoptosis, the cell dies neatly with few morphological changes including 
cell shrinkage, chromatin condensation, DNA fragmentation, membrane blebbing 
and formation of apoptotic bodies (Alberts et al., 2002; Elmore, 2007; Pollack and 
Leeuwenburgh, 2001). The dying cell is later phagocytosed either by a specialized 
phagocytic cell, macrophage, or neighbouring cell. This way permits the 
macrophage/neighbouring cell to recycle the organic components of the dead cell 
(Figure 1.6) (Zhang et al., 1997). 
Apoptosis is irreversible and energy – dependent process, which mediated by 
proteolytic enzymes called caspases. Caspases initiate the cell death by cleavage of 
specific proteins in the cytoplasm and nucleus. They are found in the cells in inactive 
form called procaspases. Activation of caspases through cleavage from other 
caspases produced a proteolytic caspase cascade (Alberts et al., 2002; Elmore, 2007). 






Figure 1.6 Comparison of the cells undergo necrosis and apoptosis. Cellular 
rupturing in necrosis caused inflammation while in apoptosis, no inflammation 














1.6 Wound Healing Modifying Agent 
As the development of fibrosis became the post – operative complication of 
the filtration surgery, wound healing modifying agent such as mitomycin – C (MMC) 
and 5 – fluorouracil (5-FU) has been used widely to enhance the surgical outcome. 
Adjunctive use of these chemotherapy drugs help to prevent the post surgical 
scarring and significantly improved the success rate of filtration surgery.  
However, these agents have the non – specific mechanism of action that can 
cause the widespread cell death and apoptosis, associated with potentially sight – 
threatening complications such as hypotony, blebitis and endophthalmitis (Vijaya et 
al., 2011; Yoon and Singh, 2004). These agents are not recommended to be applied 
repeatedly due to mentioned complications. Thus, alternative agents are needed for 
specific and effective anti – scarring treatment which can work synergistically with 
MMC or 5-FU  without serious side effects. 
 
1.6.1 Mitomycin-C 
Mitomycin – C (MMC) is used widely in glaucoma filtering surgery as a 
standard treatment due to its modulatory effects on wound healing (Khouri, 2014). 
Isolated from soil bacterium of the Streptomyces caespitosus, MMC is an anti – 
neoplastic or alkylating agent that inhibit the DNA, RNA and protein synthesis of the 
cell. It inhibits the DNA by forming linkage at the N position of Adenine and at 06 
and N position of Guanine. The most affected cell cycle is during late G-I and early 




In glaucoma surgery, MMC is use by various techniques such as sponge 
application or injection at dosage between 0.20 mg/ml and 0.40 mg/ml (Khouri, 
2014). It has increased the success rate of surgery by inhibiting the fibroblasts 
proliferation and consequent scarring of filtration bleb (Al Habash et al., 2015; 
Jampel, 1992). In spite of this, use of MMC also leads to several side effects for 
instance development of thin walled avascular/cystic blebs which might cause the 
bleb to leak and expose eyes to infection (Al Habash et al., 2015; Singh and Singh, 
2013). Previous study also reported the complication of hypotonous maculopathy, 
significant cataract and scleral necrosis exposing the ciliary body (Casson et al., 
2001; Singh et al., 1995). 
 
1.7 Anti- Vascular Endothelial Growth Factor (VEGF): Ranibizumab 
There are three common therapeutic anti – VEGF antibodies available – 
bevacizumab, ranibizumab and pegaptanib. Ranibizumab will be used for the current 
study. Ranibizumab (Lucentis TM, Genentech Inc, San Francisco, United States of 
America) is a small and fully humanized monoclonal antibody – fragment. It is 
produced in Escherichia coli cells using recombinant DNA technology. It has a low 
molecular weight of 48 kDa with a good tissue penetration characteristic (Bastion et 
al., 2011; Bochmann et al., 2011; Carneiro et al., 2012).  
Ranibizumab  was designed to bind and neutralize all isoforms and active 
degradation products of vascular endothelial growth factor A (VEGF-A). It differs 
from bevacizumab by its size and affinity for VEGF. Bevacizumab is humanized, 
murine full – length protein with two VEGF binding sites, whereas, ranibizumab is 
murine antigen – binding fragment (Fab) with only single affinity – matured VEGF 
binding site (Kim, 2007). 
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Ranibizumab is injected intravitreally which passes to all the retinal layers 
reaching the retinal pigment epithelium – choroid complex. The maximum tolerated 
single intravitreal dose of ranibizumab is 0.50 mg. Each vial of ranibizumab contains 
2.30 mg in 0.23 ml, in which overfilling is considered necessary to achieve an 
injectable dose of 0.50 mg. Ranibizumab has a short systemic half – life (12 hours) 
and a long intravitreal half – life (6 days) (Bastion et al., 2011; Bochmann et al., 
2011; Michels and Rosenfeld, 2005). 
 
 





1.8 Problem Statement and Rationale of Study 
Previous experimental animal models and clinical trials have proved that 
ranibizumab is safe and effective to be used for the treatment of diabetic macular 
oedema, subretinal choroidal neovascularisation and neovascular age – related 
macular degeneration. Lately, it has been proposed that ranibizumab can be used in 
augmentation of glaucoma filtration surgery by preventing the epi – scleral fibrosis 
after the surgery. Adjunctive use of this anti – VEGF with MMC may also overcome 
the complications that caused by MMC (Bandello et al., 2011; Elmekawey and 
Khafagy, 2014; Michels and Rosenfeld, 2005). 
However, there are a limited number of studies regarding on the role of 
ranibizumab as anti – scarring agent in glaucoma filtration surgery. Available 
evidence is insufficient to evaluate the effectiveness of this anti – VEGF treatment in 
glaucoma. Therefore, current study will be conducted to further evaluate the 
effectiveness of ranibizumab treatment in glaucoma drainage device surgery. 
 
1.9 Objectives of Study 
1.9.1 General Objective 
To determine the effects of anti – VEGF, ranibizumab, as anti – scarring 
agent on conjunctival fibroblast tissue culture following MMC. 
1.9.2 Specific Objectives 
1. To compare the level of proliferation of conjunctival fibroblasts treated at 
different concentration of ranibizumab following MMC treatment. 
15 
 
2. To determine the cytotoxic effect of different concentration ranibizumab 
following MMC treatment on conjunctival fibroblasts. 
3. To compare the level of migration and morphology of the conjunctival 
























2.1 Study Design 
2.1.1 Background of Study 
The present study is an experimental study comprises of two phases of in 
vitro experiments. Primary human conjunctival fibroblasts (HConFs) were used in 
both phases of the study. 
In the first phase, viability, proliferation and cytotoxicity assays were carried 
out in which HConFs were treated with different concentration of ranibizumab 
following single application of MMC. From these assays, the effective dose of 
ranibizumab was selected for the next phase.  
Second phase of the study involved in implantation of the glaucoma tube on 
the culture plate to observe the morphology and migration of HConFs under the 
influence of ranibizumab and MMC, both as single agent and combination. A 
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2.2 Sampling and Sample size 
Primary culture of Human Conjunctival Fibroblast (HconF) were obtained 
commercially from Sciencell Research Laboratories (California, United 
States). 
Sample size calculation was based on previous study (Md Noh et al., 2014). 
1. Level of proliferation of conjunctival fibroblasts treated at different 
concentration of ranibizumab following MMC treatment.  
6 study groups  
Consists of 1 negative control (medium only), 1 positive control 
(untreated cell), 1 standard treatment (0.40 mg/ml MMC treatment), 3 
different concentration of treatment group (Ranibizumab 0.30 mg/ml, 
0.45 mg/ml, 0.60 mg/ml in addition to 0.40 mg/ml MMC treatment). Each 
group was conducted in 4 replicates (Md Noh et al., 2014). 
 
2. Cytotoxic effect of different concentration ranibizumab following MMC 
treatment on conjunctival fibroblasts. 
5 study groups  
Consists of 1 positive control (untreated cell), 1 standard treatment (0.40 
mg/ml MMC treatment), 3 different concentration of treatment group 
(Ranibizumab 0.30 mg/ml, 0.45 mg/ml, 0.60 mg/ml in addition to 0.40 
mg/ml MMC treatment). Each group was conducted in 2 replicates. 
 
3. Level of migration and morphology of the conjunctival fibroblasts on the 
silicone tube under the influence of ranibizumab and/or MMC. 
4 study groups  
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Consists of 1 positive control (untreated cell), 1 standard treatment (0.40 
mg/ml MMC treatment), 2 treatment groups (Ranibizumab 0.45 mg/ml 
and MMC 0.40 mg/ml+Ranibizumab 0.45 mg/ml). Each group was 
conducted in 2 replicates.  
 
2.3 Ethical Approval 
This study was a part of big study entitled “Potential Anti Scarring Role of Anti – 
TGF and Anti – VEGF as Tube Drainage Device Coated Agent and Trabeculectomy 
Augmentation Agent in Glaucoma Surgery” (USM Animal Ethics 
Approval/2012/(81)(428)). It was approved on 1st September 2012 – 30th September 
2015 and extended until 31st January 2019. 
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This study received USM Research University Individual grant (RUI 
1001/PPSP/813069) for the purchased of primary cell culture, consumables items 





2.5 Materials  
2.5.1 Chemicals, Reagent and Solutions 
All chemicals, reagent and solutions used in this study are listed in Table 2.1 
2.5.2 Commercial Kits and Consumables 
All commercial kits and consumables used in this study are listed in Table 
2.2 
2.5.3 Computer Application Programs and Software 
All computer application programs and software used in this study are listed 
in Table 2.3 
2.5.4 Drugs  
All drugs used in this study are listed in Table 2.4 
2.5.5 Laboratory Apparatus and Equipments 










Table 2.1 List of chemicals, reagent and solutions 
No. Chemicals/ Reagent/ Solutions Supplier 
1 Dimethyl sulphoxide (DMSO) Sigma-Aldrich, UK 
2 alamarBlue Cell viability assay reagent Thermo Scientific, USA 
3 Fetal bovine serum (FBS) Invitrogen, USA 
4 Basal Medium  Sciencell, USA 
5 Fibroblast growth supplement Sciencell, USA 
6 Penicilin/Streptomycin Sciencell, USA 
7 Dulbecco’s Phosphate-Buffered Solution (DPBS) Sciencell, USA 
8 Poly-L-Lysine Sciencell, USA 
9 Trypsin/EDTA solution Sciencell, USA 
10 Trypsin Neutralization Solution Sciencell, USA 
11 Trypan blue solution (0.4%) Sigma-Aldrich, UK 











Table 2.2 List of commercial kits and consumables 
No. Consumables / Commercial Kits Supplier 
1 Cell culture flasks (25cm2 and 75cm2) SPL Life Sciences, Korea 
2 Cell culture dish 35mm SPL Life Sciences, Korea 
3 Cell culture plate (6, 24 and 96-well plate) SPL Life Sciences, Korea 
4 Serological pipette (5ml and 10ml) SPL Life Sciences, Korea 
5 Cryovial SPL Life Sciences, Korea 
6 5ml centrifuge/conical tube SPL Life Sciences, Korea 
7 10ml centrifuge/conical tube Biologix,USA 
8 Micropipette tips  Axygen, USA 
9 Annexin V-FITC Apoptosis Detection Kit Invitrogen, USA 

















Table 2.3 List of computer application programs and software 
No. Software Packages Supplier 
1 Image – Pro Express Software Media Cybernetics, USA 
2 CellQuest Software BD Biosciences, USA 
3 MagellanData Analysis Software 4.0 Tecan, Austria 
4 Quanta FEG 450 Fei, Netherlands 
5 Excel Software Microsoft Corp, USA 
6 IBM SPSS Statistics 22 IBM Corp 
 
 
Table 2.4 List of drugs 
No. Drugs Supplier 
1 Mitomycin – C  Kyowa Hakko Kogyo Co, Japan 
2 Ranibizumab/Lucentis® Novartis, Switzerland 
 
 
 
 
 
 
 
 
